[{"id":"5c523880-f8a6-448f-8403-e3010aefe575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03772925","created_at":"2021-01-18T18:39:51.839Z","updated_at":"2025-02-25T14:40:05.004Z","phase":"Phase 1","brief_title":"Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03772925","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pevonedistat (MLN4924) • Beleodaq (belinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/16/2025","primary_completion_date":" 06/16/2025","study_txt":" Completion: 06/16/2025","study_completion_date":" 06/16/2025","last_update_posted":"2025-02-14"},{"id":"5f277fe7-343a-4221-8527-c095bdf402da","acronym":"","url":"https://clinicaltrials.gov/study/NCT04175912","created_at":"2021-01-29T07:20:00.803Z","updated_at":"2025-02-25T16:37:37.268Z","phase":"Phase 2","brief_title":"Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver","source_id_and_acronym":"NCT04175912","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • UBE2M • NEDD8","pipe":"","alterations":" ","tags":["CD4 • UBE2M • NEDD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 11/27/2023","primary_completion_date":" 11/27/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"b3cbc60c-b805-4974-b2a9-560e9eb38edd","acronym":"NCI-2018-00315","url":"https://clinicaltrials.gov/study/NCT03479268","created_at":"2021-01-18T17:08:37.744Z","updated_at":"2025-02-25T17:35:59.375Z","phase":"Phase 1","brief_title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03479268 - NCI-2018-00315","lead_sponsor":"City of Hope Medical Center","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2025-01-29"},{"id":"aecf3ac5-9504-4f3a-9a5f-7cc5aaedb65d","acronym":"NCI-2019-03212","url":"https://clinicaltrials.gov/study/NCT03965689","created_at":"2021-01-18T19:30:37.082Z","updated_at":"2024-07-02T16:35:02.796Z","phase":"Phase 2","brief_title":"Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy","source_id_and_acronym":"NCT03965689 - NCI-2019-03212","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression","tags":["BRAF • ALK • ROS1 • B2M • RAD51 • CD4 • NQO1 • NTRK • SLC7A11 • UBE2M • ATF3 • NAE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation • ROS1 positive • SLC7A11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 03/20/2025","study_completion_date":" 03/20/2025","last_update_posted":"2024-05-17"},{"id":"db802908-d352-4788-a1a5-ab4e959f4c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009240","created_at":"2024-03-12T22:20:15.146Z","updated_at":"2024-07-02T16:35:15.595Z","phase":"Phase 1","brief_title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT03009240","lead_sponsor":"City of Hope Medical Center","biomarkers":" MIR155 • NFKB1","pipe":" | ","alterations":" miR-155 expression • NFKB1 expression","tags":["MIR155 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-03-08"},{"id":"1c457901-9a43-4dcc-9740-e44b1b37ea65","acronym":"NCI-2018-03465","url":"https://clinicaltrials.gov/study/NCT03862157","created_at":"2021-01-18T19:03:08.762Z","updated_at":"2024-07-02T16:35:23.829Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT03862157 - NCI-2018-03465","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA","pipe":" | ","alterations":" NPM1 mutation • CEBPA mutation • PDGFRA rearrangement","tags":["ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CEBPA mutation • PDGFRA rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"87d4d712-7f6d-4ed0-aac5-37b3977813e1","acronym":"ADVL1615","url":"https://clinicaltrials.gov/study/NCT03323034","created_at":"2021-01-18T16:24:22.514Z","updated_at":"2024-07-02T16:35:30.233Z","phase":"Phase 1","brief_title":"Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03323034 - ADVL1615","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/11/2018","start_date":" 01/11/2018","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-06"},{"id":"b69d0397-c02d-49d3-b488-bd1e06f73acf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04712942","created_at":"2021-01-19T20:52:51.707Z","updated_at":"2025-02-25T14:51:57.702Z","phase":"Phase 2","brief_title":"Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat","source_id_and_acronym":"NCT04712942","lead_sponsor":"University of Leipzig","biomarkers":" KIT • NPM1 • CD34","pipe":" | ","alterations":" NPM1 mutation","tags":["KIT • NPM1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • pevonedistat (MLN4924)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2023-08-21"},{"id":"45d08cf4-c299-461e-b44a-e62391261757","acronym":"","url":"https://clinicaltrials.gov/study/NCT03745352","created_at":"2021-01-29T07:18:20.168Z","updated_at":"2024-07-02T16:35:44.652Z","phase":"Phase 2","brief_title":"Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03745352","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • pevonedistat (MLN4924)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/20/2019","start_date":" 05/20/2019","primary_txt":" Primary completion: 08/19/2021","primary_completion_date":" 08/19/2021","study_txt":" Completion: 08/19/2021","study_completion_date":" 08/19/2021","last_update_posted":"2023-06-27"},{"id":"6d40fd33-6136-41b7-a8de-83b9fc9810c5","acronym":"PEVOLAM","url":"https://clinicaltrials.gov/study/NCT04090736","created_at":"2021-01-18T20:01:13.130Z","updated_at":"2025-02-25T14:51:32.410Z","phase":"Phase 3","brief_title":"Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy","source_id_and_acronym":"NCT04090736 - PEVOLAM","lead_sponsor":"PETHEMA Foundation","biomarkers":" FLT3 • IDH1 • IDH2 • NPM1 • CD4","pipe":"","alterations":" ","tags":["FLT3 • IDH1 • IDH2 • NPM1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 09/24/2019","start_date":" 09/24/2019","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2022-09-10"},{"id":"836f4bce-9009-4914-929c-c6bb7d4697d9","acronym":"NCI-2019-06910","url":"https://clinicaltrials.gov/study/NCT03459859","created_at":"2022-10-04T15:55:39.371Z","updated_at":"2025-02-25T14:50:55.754Z","phase":"Phase 1","brief_title":"Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS","source_id_and_acronym":"NCT03459859 - NCI-2019-06910","lead_sponsor":"Justin Watts, MD","biomarkers":" CDT1","pipe":"","alterations":" ","tags":["CDT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • pevonedistat (MLN4924)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/21/2018","start_date":" 05/21/2018","primary_txt":" Primary completion: 06/25/2021","primary_completion_date":" 06/25/2021","study_txt":" Completion: 06/25/2021","study_completion_date":" 06/25/2021","last_update_posted":"2021-12-28"},{"id":"814e661a-25f3-48a9-8987-0deeebc70170","acronym":"PEVOBINE","url":"https://clinicaltrials.gov/study/NCT04985656","created_at":"2021-08-02T14:53:04.830Z","updated_at":"2024-07-02T16:36:23.698Z","phase":"Phase 2","brief_title":"A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes","source_id_and_acronym":"NCT04985656 - PEVOBINE","lead_sponsor":"Takeda","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pevonedistat (MLN4924) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 01/08/2024","primary_completion_date":" 01/08/2024","study_txt":" Completion: 11/08/2024","study_completion_date":" 11/08/2024","last_update_posted":"2021-09-29"},{"id":"e009edf1-1075-44ee-b1c9-f640aad1afd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01415765","created_at":"2021-01-18T05:49:43.360Z","updated_at":"2024-07-02T16:36:52.371Z","phase":"Phase 1/2","brief_title":"MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma","source_id_and_acronym":"NCT01415765","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CARD11","pipe":"","alterations":" ","tags":["CARD11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • pevonedistat (MLN4924) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/15/2011","start_date":" 07/15/2011","primary_txt":" Primary completion: 01/07/2014","primary_completion_date":" 01/07/2014","study_txt":" Completion: 01/07/2014","study_completion_date":" 01/07/2014","last_update_posted":"2019-12-17"}]